TCX-201 and TCX-101 data presented at AACR 2026

Tacalyx presented two posters at the AACR Annual Meeting 2026 in San Diego on April 21, 2026.

Poster 5631 — TCX-201

TCX-201, a novel ADC targeting a specific tumor-associated carbohydrate antigen (TACA) with excellent preclinical efficacy, PK and safety profile in solid tumor models.

F. Muraca, S. Grunwald, W. Winkler, K. E. G. Soto, A. Srivastava, C. Lange, J. Engela, P. Sondermann, M. Ocker

• TCX-201 was tested with three payloads (MMAE DAR4, exatecan DAR8, deruxtecan DAR8). In vitro potency tracked the amount of target on the cell surface, including patient-derived cell lines from colorectal (2 of 5) and pancreatic (6 of 8) tumors.
• The MMAE variant reduced tumor growth dose-dependently in cell line-derived xenografts (T/C of 5.7 % at 7 mg/kg in Capan-2 and 2.8 % in Colo-205, with 33 % complete responses in Colo-205).
• In a patient-derived xenograft from metastatic colorectal cancer, TCX-201 MMAE reached a complete response rate above 80 % at 5 and 10 mg/kg.
• Half-life in mice was about five days for all linker-payload combinations; exposure was confirmed in non-human primates. A single-dose non-GLP study in cynomolgus monkeys showed only transient, mild changes in clinical chemistry.

Poster 5584 — TCX-101

TCX-101, a trispecific T-cell engager (TcE) co-targeting a tumor-associated carbohydrate (TACA) antigen and a tumor-associated protein antigen (TAA) for the treatment of solid tumors with enhanced preclinical activity.

K. E. G. Soto, F. Muraca, S. Grunwald, W. Winkler, C. Lange, A. Srivastava, J. Engela, P. Sondermann, M. Ocker

• Four trispecific formats bound cancer cells more strongly than single-arm controls, which points to bivalent engagement of TACA and TAA.
• In co-culture with human T cells, the formats killed cancer cells of several origins in a concentration-dependent way. Knockout of either the TACA or the TAA reduced binding and killing.